Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Nab-paclitaxel|DRUG: Paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Normale Saline Solution
Sponsor: Merck Sharp & Dohme LLC